Q2 revenue: €63.0m, +7.0% (flat at constant scope) after +7.7% in Q1 / vs. €65.5m expected Pharmagest: €45.1m, +2.7% / vs. €46.3m expected Axigate Link: €9.9m, +20.7% (+2.7% organic) / in line E-Connect: €2.8m, -30.0% / vs. €4.2m expected Medical Solutions: €4.8m, +100% (-4.2% organic) / vs. €4.6m expected H1 revenue: €124.5m, +7.3% / +1.4% organic Contribution from acquisitions: €6.3m Ségur contribution: €0.6m H1 recurring revenues (ARR): +8.4% to €55.7m (+4.7% organic) Annualized recurring revenues (ARR): €111.1m, +8.8%